ImmunityBio (ImmunityBio) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Change In Receivables?

ImmunityBio's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means ImmunityBio's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

ImmunityBio's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means ImmunityBio's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

ImmunityBio's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ImmunityBio's Days Sales Outstanding for the three months ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ImmunityBio's liquidation value for the three months ended in Mar. 2024 was $-921.17 Mil.

ImmunityBio Change In Receivables Historical Data

The historical data trend for ImmunityBio's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Change In Receivables Chart

ImmunityBio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

ImmunityBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial													-	-	-	-	-

ImmunityBio Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

ImmunityBio (NAS:IBRX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ImmunityBio's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.04	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, ImmunityBio's accounts receivable are only considered to be worth 75% of book value:

ImmunityBio's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	170.495	-	1091.662	+	0.75 * 0	+	0.5 * 0
=	-921.17

ImmunityBio Change In Receivables Related Terms

Thank you for viewing the detailed overview of ImmunityBio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ImmunityBio (ImmunityBio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (NAS:IBRX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

26CA:Germany

Address

3530 John Hopkins Court, San Diego, CA, USA, 92121

Website

https://www.immunitybio.com

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.

Executives

Patrick Soon-shiong	director, 10 percent owner, officer: See remarks	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
California Capital Equity, Llc	10 percent owner	10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Cambridge Equities, Lp	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Mp 13 Ventures, Llc	10 percent owner	9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Michael D Blaszyk	director	C/O NANTKWEST, INC., 2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
John Owen Brennan	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Wesley Clark	director	C/O ARGYLE SECURITY ACQUISITION CORP., 200 CONCORD PLAZA, SUITE 700, SAN ANTONIO TX 78216
Regan J Lauer	officer: Chief Accounting Officer	4250 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Richard Adcock	officer: Chief Executive Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Linda Maxwell	director	1040 SPRING STREET, SILVER SPRING NC 27709
Christobel Selecky	director	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David C. Sachs	officer: Chief Financial Officer	C/O IMMUNITYBIO, INC., 3530 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Frederick W Driscoll	director